Particle News: Latest BioNTech SE news

BioNTech to Acquire CureVac for $1.25 Billion to Drive mRNA Cancer Therapy

Approved by both companies’ boards, the all-stock acquisition is slated to close in 2025 pending regulatory approval.

Bristol Myers Squibb and BioNTech partner on $11 billion bispecific antibody cancer drug

UK Finalizes £1bn BioNTech Deal to Advance mRNA Cancer Vaccines and AI Research

Biontech Reports Q1 Loss as Focus Shifts to mRNA Cancer Therapies

Same-Arm Boosters Found to Enhance Early Vaccine Response

HHS Secretary RFK Jr. Weighs Removing COVID-19 Vaccine From Childhood Schedule

Biontech Reports €700 Million Loss and Plans Workforce Restructuring

Moderna Wins Patent Case Against BioNTech and Pfizer Over mRNA Technology